FDA, NIH partnership promises better science, faster reviews

The FDA and the NIH say they'll collaborate on a new program aimed at improving the regulatory science used to review the safety and efficacy of new drugs, promising that better science will lead to swifter decision-making.

"We have allowed the arm of regulatory science to become weak and underdeveloped," FDA Commissioner Margaret Hamburg told reporters. If not fixed, "instead of pulling us into an exalted future, we will row in circles."

To get the partnership up and running, the agencies agreed to form a committee of six top scientists drawn from both organizations. They will provide $6.75 million over three years to fund regulatory science research. President Obama's proposed budget also includes $25 million to improve the science in use at government agencies. The regulators even announced a few priorities, like shortening the time it takes to test the potency of flu vaccines. Instead of three or four months, the agencies believe that wait can be halved.

HHS Secretary Kathleen Sebelius promised that "this is going to mean that new treatments are safer and available sooner."

Anyone outside the vaccine field, though, isn't likely to shorten their timelines on regulatory reviews anytime soon. If scientific committees and small budgets were all it took to transform the FDA's review record, the average cost of development would be much smaller than it is today.

- here's the story from the Los Angeles Times
- and here's the Bloomberg piece

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.